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ABSTRACT
Adrenocortical carcinoma (ACC) is a rare aggressive tumor with poor prognosis 
when metastatic at diagnosis. The tumor biology is still mostly unclear, justifying the 
limited specificity and efficacy of the anti-cancer drugs currently available. This study 
reports the first proteomic analysis of ACC by using two-dimensional-differential-in-
gel-electrophoresis (2D-DIGE) to evaluate a differential protein expression profile 
between adrenocortical carcinoma and normal adrenal. Mass spectrometry, associated 
with 2D-DIGE analysis of carcinomas and normal adrenals, identified 22 proteins in 
27 differentially expressed 2D spots, mostly overexpressed in ACC. Gene ontology 
analysis revealed that most of the proteins concurs towards a metabolic shift, called 
the Warburg effect, in adrenocortical cancer. The differential expression was validated 
by Western blot for Aldehyde-dehydrogenase-6-A1,Transferrin, Fascin-1,Lamin 
A/C,Adenylate-cyclase-associated-protein-1 and Ferredoxin-reductase. Moreover, 
immunohistochemistry performed on paraffin-embedded ACC and normal adrenal 
specimens confirmed marked positive staining for all 6 proteins diffusely expressed 
by neoplastic cells, compared with normal adrenal cortex.
In conclusion, our preliminary findings reveal a different proteomic profile in 
adrenocortical carcinoma compared with normal adrenal cortex characterized by 
overexpression of mainly metabolic enzymes, thus suggesting the Warburg effect 
also occurs in ACC. These proteins may represent promising novel ACC biomarkers 
and potential therapeutic targets if validated in larger cohorts of patients.
INTRODUCTION
Adrenocortical tumors are rather common, 
with a prevalence of about 9% in the older age, and 
mostly benign adenomas (ACA). On the other hand, 
adrenocortical carcinomas (ACC) are rare and aggressive 
tumors with an incidence of 1-2 cases/million people/year 
and poor prognosis (5-year survival rate around 30%) 
[1-4]. Survival rate drops below 10% when metastasis is 
found at diagnosis.
In spite of recent studies on the genetics and 
molecular biology of this neoplasia [5-9], its pathogenesis 
is still not completely understood: new diagnostic and 
prognostic biomarkers as potential therapeutic targets are 
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sought to improve patient clinical management.
Genetic and molecular studies of the tumor provide 
information on gene alterations and derangement of the 
corresponding intracellular pathways. Proteomic studies 
analyze the physiological or pathological complex of 
cell proteins, complementing genomic studies which 
quantitatively and qualitatively examine the end-products 
of those synthetic cell pathways which may have 
undergone post-translational modification.
In this paper we present the results of the first 2 
dimensional-differential-in-gel electrophoresis (2D-DIGE) 
proteomic study performed on malignant adrenocortical 
tumors compared with normal adrenals, in an effort to 
discover new therapeutic targets for ACC. 
RESULTS 
Differential proteomic profile in ACC versus 
normal adrenal
The study included 10 patients with histological 
diagnosis of adrenocortical cancer (ACC), who underwent 
surgery without any previous anticancer treatment. 
Clinical characteristics of patients are reported in Table 1. 
Protein expression profiles for ACC (n=11) and 
normal adrenal tissue (n=8) lysates obtained by separating 
samples on 10 parallel 2D gels were compared using 
2D-DIGE technology (Fig.1 suppl.). After Decyder 
analysis of fluorescent gel images, a total of 250 spots 
were matched across all gels. Gel to gel matching of 
the standard spot maps from each gel was performed 
using DeCyder BVA module. This allowed statistical 
analysis of changes in protein abundance between 
samples referred to the internal standard. The analysis 
with BVA module revealed quantitative changes in 60 
spots in all samples analyzed, with statistical variance of 
tumor versus normal spot volume ratios within the 95th 
confidence level (p<0.05) (Fig.1B). Due to an intrinsic 
variability associated with patient characteristics and 
tissue heterogeneity, a stringent criterion was chosen, so 
that, only proteins found in at least 80% of the 19 tissue 
specimens (11 ACC and 8 normal adrenals) analyzed in 
all gels with more than a statistically significant (p<0.05) 
2-fold change were considered for further analysis. A total 
of 60 protein spots were selected and excised from the 
preparative gel (Fig.1A) for tryptic digestion and mass 
spectrometry analysis. Analyzed proteins were identified 
through their peptide spectrum match (PSM) using 
Fig.1: 2D-DIGE reveals a profile of 60 protein spots differentially expressed in ACC versus normal adrenal. (A) The 
60 marked spots in the 2D-DIGE preparative gel correspond to those found differentially expressed between ACC and normal adrenal 
samples. The spots of interest were picked and subsequently identified by NanoLC-nanoESI-MS/MS and peptide mass fingerprinting 
analysis as reported in Tab.2. (B) Fold increase expression values for the 60 spots differentially expressed between ACC and NOR as 
resulted by Decyder Software analysis of the 10 2D-DIGE gels run, reported for each of the 60 marked spots in the preparative gel. Spot 
identification number (Pos.) as in preparative gel, p-value and average ratio (Av. Ratio) of expression between ACC and normal adrenal 
samples, evaluated against the internal standard are given for each spot. Only average ratios higher or lower than +2 or -2 were considered. 
Differences in spot expression between ACC and NOR are considered statistically significant with a p<0.05, Student’s t-test. 
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MASCOT software to interrogate Swiss-Prot database. 
Among the 60 spots examined, 27 were finally 
selected for further analysis. In fact, some of the initially 
picked spots were discarded as, at variance with those 
selected, they were not present in 100% of the run gels. 
Moreover, some of the proteins in the identified 60 spots 
showed different isoforms or presented post-translational 
modifications, characterized by different isoelectric point 
Table 1: Patient  characteristics. Clinical characteristics of the 10 patients affected by ACC and included in the 
proteomic analysis. Age at surgery, sex, hormonal activity of the tumor, diameter, Ki67, Weiss score and stage of 
the tumor, according to the new ACC classification from ENSAT [13] are indicated. For one patient, 2 independent 
samples were taken in different regions of the tumor biopsy and were analyzed as independent specimens (ACC2 
and ACC2a). –: not defined; NS: non secreting; CORT: cortisol, T: testosterone; DHEAS: dehydroepiandrosterone 
sulfate; DELTA4: androstenedione.
 
PATIENTS AGE(years) SEX
HORMONAL 
ACTIVITY
DIAMETER
(cm)
Ki67 
(%) WEISS STAGE
ACC1 71 F NS 9 10 7 4
ACC2
ACC2a 58 F NS 13 90 8 3
ACC3 36 F CORT 6.7 15 5 3
ACC4 45 F DHEAS, T, DELTA4 7.5 5 6 2
ACC11 4 F - 4 <5 3 -
ACC13 46 F NS 6 <1 4 2
ACC20 58 F CORT 7 40 8 3
ACC21 23 F T, DELTA4 5 1 3 1
ACC22 62 F NS 2.5 10 6 2
ACC26 1 F - 9 20 6 -
Fig.2: Heat-map for the 27 selected spots identifies two independent clusters. Hierarchical analysis of spot expression levels in 
19 unilateral adrenocortical tissue specimens from 10 different ACC patients (11 ACC samples) and 8 normal adrenals (NOR). Hierarchical 
clustering of samples based on 2D-DIGE analysis of the 27 protein spots (right) differentially expressed between ACC and NOR. The heat-
map shows expression level of the 27 protein spots in each sample run on 10 2D-DIGE independent gels. Samples and separating gels are 
indicated at the bottom. The dendrogram shows the degree of similarity of protein expression pattern between tumors and normal tissues. 
The shorter the branches, the more similar the two joined samples. Two expression patterns of tumor tissue samples resemble more normal 
adrenals. Heat-map analysis confirmed a similar level of expression in the two independent specimens obtained from ACC2 (ACC2 and 
ACC2a). The lowest and highest intensity values for each protein are in green and red according to the indicated color scale.
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Table 2: List of the 22 differentially expressed proteins between adrenocortical tumors and normal adrenals identified 
by NanoLC-nanoESI-MS/MS. The table shows the MS output list of the 22 proteins identified in the 27 chosen spots that 
were significantly up- or down-regulated in ACC versus NOR. Fold differences were calculated within the BVA module 
of DeCyder. All differences are statistically relevant, with p<0.05. Some proteins were present in different spots, generally 
represented by post-translational modifications. When multiple proteins were identified in a single spot, only those with the 
number of covering peptides and coverage score over the cut-off values and consistent with the attended pI and MW were 
considered. The % coverage > 5 or the peptide number ≥ 2 criterion was adopted. Accession number, % coverage, number of 
covering peptides, peptide spectrum match (PSM), aminoacid number (AA), molecular weight (MW), calculated isoelectric 
point (calc. pI), score and spot number are indicated.
Accession Coverage PSM # Peptides # AA MW [kDa] pI Score Description Spot
gi4557871 41,26 65 29 698 77,0 7,1 259,38 transferrin [Homo sapiens] 8
gi21614499 37,88 43 23 586 69,4 6,3 146,39 ezrin [Homo sapiens] 9
gi63055049 13,40 15 8 612 68,2 6,7 75,80 phosphoglucomutase 2 [Homo sapiens] 11
gi63055049 10,62 9 6 612 68,2 6,7 45,66 phosphoglucomutase 2 [Homo sapiens] 12
gi4506467 21,78 24 13 583 68,5 6,4 77,36 radixin [Homo sapiens] 13
gi4506467 21,78 24 13 583 68,5 6,4 77,36 radixin [Homo sapiens] 14
gi4506467 21,78 24 13 583 68,5 6,4 77,36 radixin [Homo sapiens] 15
gi66346721 6,56 4 4 640 70,7 7,6 32,12
mitochondrial phosphoenolpyruvate 
carboxykinase 2 isoform 1 precursor 
[Homo sapiens]
16
gi5031875 14,69 9 7 572 65,1 6,8 33,97 lamin A/C isoform 2 [Homo sapiens] 30
gi153218646 13,24 11 6 521 60,1 8,8 35,70
cytochrome P450, family 11, 
subfamily A, polypeptide 1 isoform a 
precursor [Homo sapiens]
34
gi20070125 27,95 29 13 508 57,1 4,9 179,85 prolyl 4-hydroxylase, beta subunit precursor [Homo sapiens] 33
gi20070125 29,72 108 16 508 57,1 4,9 518,91 prolyl 4-hydroxylase, beta subunit precursor [Homo sapiens] 32
gi18201905 8,60 6 3 558 63,1 8,3 40,59 glucose phosphate isomerase [Homo sapiens] 36
gi195972866 5,11 4 2 584 58,8 5,2 11,84 keratin 10 [Homo sapiens] 37
gi4885281 19,00 14 9 558 61,4 7,8 79,49 glutamate dehydrogenase 1 [Homo sapiens] 39
gi4507115 9,13 7 4 493 54,5 7,2 32,94 fascin 1 [Homo sapiens] 41
gi91199540 14,54 15 6 509 54,1 7,9 79,58 dihydrolipoamide dehydrogenase precursor [Homo sapiens] 42
gi50301238 10,73 8 4 522 56,2 8,5 35,93 glutathione reductase [Homo sapiens] 44
gi50301238 17,05 14 7 522 56,2 8,5 59,59 glutathione reductase [Homo sapiens] 45
gi50301238 17,05 14 7 522 56,2 8,5 59,59 glutathione reductase [Homo sapiens] 46
gi11095441 8,79 8 5 535 57,8 8,5 37,21 aldehyde dehydrogenase 6A1 precursor [Homo sapiens] 47
gi4757810 12,84 10 6 553 59,7 9,1 40,87
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit precursor [Homo sapiens]
48
gi4757810 12,84 10 6 553 59,7 9,1 40,87
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit precursor [Homo sapiens]
49
gi111118981 13,44 12 6 491 53,8 8,4 38,38 ferredoxin reductase isoform 1 precursor [Homo sapiens] 50
gi5453595 18,32 10 7 475 51,6 8,02 37,18 adenylyl cyclase-associated protein [Homo sapiens] 53
gi48255966 16,73 17 8 508 56,9 8,1 74,66 UDP-glucose pyrophosphorylase 2 isoform a [Homo sapiens] 53
gi4758958 10,15 10 3 404 45,5 5,0 48,63
cAMP-dependent protein kinase, 
regulatory subunit alpha 2 [Homo 
sapiens]
58
gi17402865 28,28 14 7 297 33,4 7,3 74,87 thiosulfate sulfurtransferase [Homo sapiens] 60
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(pI) and molecular weight (MW). When multiple proteins 
were identified in a single spot, only those exhibiting the 
number of covering peptides and coverage score over 
the cut-off values, together with a consistent calculated 
pI and MW, were considered. Due to the extremely 
small amount of downregulated proteins between ACC 
and normal adrenal, most of the detected spots were 
upregulated. Tab.2 summarizes the characteristics of the 
spots and correspondent 22 proteins whose expression was 
modulated with regard to normal tissue extracts.
Hierarchical clustering
To further investigate the clinical value of the 
protein expression profile detected in our specimens, we 
performed with DeCyder a specific hierarchical clustering 
analysis of the 27 selected spots. Fig.2 shows the heat map 
obtained from spot fold variation in expression compared 
with the internal standard in each sample separated on 
10 independent 2D-DIGE gels. The expression profile 
separated samples into two distinct homogeneous clusters 
corresponding to malignant tumors (overexpression in red) 
and normal adrenals (downregulation in green), except for 
2 out of 11 ACC samples (18%) which were misclassified 
in the normal adrenal cluster. All normal adrenal samples 
were correctly classified with no false positive. 
Functional classification of the identified proteins 
and biological network analysis
Proteins identified by mass spectrometry were 
classified by subcellular localization and biological 
processes by BINGO software analysis. As expected, most 
of the identified proteins were related to the intracellular 
compartment and more precisely to the cytosol and 
mitochondria (Fig.3A). Regarding the major biological 
processes involved, these proteins were mainly associated 
with induced metabolism (Fig.3B). Enrichment analysis 
of biological processes obtained through BINGO software 
(Fig.3D), revealed 15 biological processes enriched in 
ACC compared with normal controls sorted into the lowest 
p-value and corrected p-value (Benjamini-Hochberg 
correction) of 0.01. These processes are mainly involved 
in metabolism of small molecules, organic acids, ketones, 
glucose, monosaccharides, alcohols and carbohydrates, 
in cell redox homeostasis and generation of metabolite 
precursors and energy (Fig.3D). Instead, the enrichment 
analysis of cellular compartments showed a prevalent 
distribution of the 22 proteins differentially expressed at 
intracellular and mitochondrial level (Fig.3C).
Fig.3: Functional classification of identified proteins and biological network analysis. Cellular component (A) and biological 
processes (B) interested by the 22 differentially expressed proteins assessed by BINGO search and summarized according to functions and 
location in the cell. For each biological process and cellular component the number of proteins in each class is given. Enrichment analysis of 
cellular component (C) and biological process networks (D) generated by BINGO software for the 22 differentially expressed proteins. The 
color bar in right lower quadrant indicates the level of significance from low (yellow) to high (orange). The size of each node is proportional 
to the number of proteins annotated with that term. Only statistically significant sub-networks are shown in the figure (p<0.01).
Oncotarget5700www.impactjournals.com/oncotarget
Validation of differentially expressed proteins by 
Western blot and immunohistochemical analysis
To confirm modulation in the expression of proteins 
identified by MS after 2D-DIGE analysis, we performed 
Western blot of the same pooled ACC and normal adrenal 
specimens. We decided to confirm a set of proteins from 
the 22 analyzed because of the central role they play 
in some of the pivotal signaling pathways involved in 
tumorigenesis and cancer progression. Western blot 
analysis of lysates containing either all ACC samples 
(ACC) or all normal adrenal samples (NOR), confirmed 
the differential expression of Aldehyde-dehydrogenase-
6-A1 (ALDH6A1, A), Transferrin (B), Fascin-1 (C), 
Lamin A/C (D), Adenylate-cyclase-associated-protein-1 
(CAP-1, E) and Ferredoxin reductase (FNR, F) in 
ACC vs. normal adrenals as observed from 2D-DIGE 
analysis (Fig.4). In particular, in ACC, all proteins were 
significantly upregulated compared with normal adrenal 
(Fig.4G), in agreement with the expression ratio observed 
in 2D-DIGE analysis. 
To further and independently validate the 
differentially expressed proteins and localize them into 
the adrenal tissue, we performed immunohistochemistry 
for all six proteins on the same ACC and normal adrenal 
samples (Fig.5). A marked positive granular signal for 
ALDH6A1 was evident in the cytoplasm of almost all 
tumor cells, probably associated with mitochondria 
(Fig.5A), while a more diffuse cytosolic positivity was 
detected for Transferrin (Fig.5B) and Fascin-1 (Fig.5C) in 
ACC slices. Marked positivity to Lamin A/C (Fig.5G) was 
evident in ACC in nuclei and to CAP-1 (Fig.5H) and FNR 
in cytosol (Fig.5I). Conversely, immunohistochemistry 
was negative for all 6 markers in normal adrenals (Fig.5D, 
E, F, K, L), except for a mild positivity to Lamin A/C 
Fig.4: Western blot analysis of six proteins differentially 
expressed in ACC and normal adrenal. Differential 
expression of ALDH6A1 (A), Transferrin (B), Fascin-1 (C), 
Lamin A/C (D), CAP-1 (E) and Ferredoxin reductase (FNR, F) 
as detected by a representative Western blot of the same pool 
of ACC and normal adrenal (NOR) samples used in 2D-DIGE. 
(G) Bar charts show mean±SE of relative expression levels for 
identified proteins vs actin, used as internal loading control and 
determined by densitometric analysis; n=3 independent Western 
blots. Statistical analysis with Student’s t test: *p<0.01, ** 
p<0.005.
Fig.5: Immunohistochemical detection of the six 
proteins differentially expressed in ACC and normal 
adrenal. Representative images of immunohistochemistry 
performed on tumor specimens (n=4) and normal adrenals (n=3) 
revealed marked positivity to ALDH6A1 (A), Transferrin (B), 
Fascin-1 (C), CAP-1 (H) and Ferredoxin reductase (I) in the 
cytosol of almost all tumor cells in the field, compared to no 
positivity in normal adrenal, respectively (D-F, K-L). Nuclear 
positivity to Lamin A/C was diffused in tumor cells (G) and less 
expressed in normal adrenal cortex (J).
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(Fig.5J), nevertheless lower than the corresponding ACC 
(Fig.5G). 
DISCUSSION
Differential display analysis of cancer tissues 
compared with normal counterparts enables definition of 
specific proteomic profiles characterizing the pathology. 
Our study, for the first time, applies a 2D-DIGE 
approach to the analysis of ACC compared with normal 
adrenal, resulting in identification of a protein pattern 
specifically overexpressed in ACC. Until now, mostly only 
transcriptome analysis had been performed on ACC [5-
9]. Despite permitting comprehensive analysis of mRNA 
transcripts, these studies cannot demonstrate that the 
observed mRNA modulation corresponds to a consequent 
modulation of the encoded proteins. Indeed, steady-state 
transcript abundance only partially predicts protein levels 
in various systems [10]. Immunohistochemistry associated 
with this approach is limited to the expression analysis 
of already identified proteins. Moreover, apart from tissue 
microarray analysis (TMA), not yet been applied to ACC, 
a simultaneous analysis of the protein complexes likely 
involved in mediating cancer progression can only be 
obtained through a proteomic approach. So far, only 2 
proteomic studies have been performed in adrenocortical 
cancer [11]. However, neither study applied 2D-DIGE, 
but rather narrow range isoelectric focusing (IEF) 
associated with reversed phase liquid chromatography 
[11] or conventional 2D electrophoresis [12], failing to 
directly compare normal and tumor samples. Moreover, 
classification of tumor and patient characteristics was 
not conducted according to the accepted ENSAT criteria 
[13]. Conversely, the 2D-DIGE technique enables direct 
comparison between tumor and normal samples on the 
same 2D gel, thus reducing technical variability which 
could affect any detected differences. Moreover, the 
introduction of fluorescent dyes to mark the samples to 
be compared, exponentially increases the sensitivity 
of detection. Finally, the use of an internal standard, 
consisting of a mixture of equal amounts of all the 
samples to be analyzed, allows precise quantification of 
protein differential expression regardless of the number of 
matched gels and arbitrary matching of normal and tumor 
samples in each gel.
The proteomic approach has been widely used to 
identify useful biomarkers for early detection of various 
tumors (prostate, breast, colon). In particular, this method 
has had a relevant clinical impact when biomarkers 
identified in the tumor were also found to be differentially 
expressed in the bloodstream [14]. 
In our study, we compared the proteomic profile 
of ACC specimens from 10 affected patients with that 
from normal adrenals. We identified 22 proteins in 27 
spots differentially expressed in the pathologic versus 
normal condition. These proteins can be considered 
promising biomarker candidates in tumor development 
and progression. Hierarchical classification of specimens, 
based on their protein expression profiles with no a priori 
assumption, was associated with the histopathology-based 
diagnosis of ACC [10], indicating that the proteome profile 
may well reflect the histological features of the tissue. 
In agreement with Kjellin and colleagues [11], 
who however limited their analysis to the microsomal 
enriched protein fraction, gene ontology analysis of the 
22 differentially expressed proteins found in our study 
highlighted significant changes in the glucose metabolic 
pathways in ACC; this strongly indicates a metabolic 
shift from aerobic respiration to aerobic glycolysis also 
in adrenocortical tumors. This metabolic reprogramming, 
also known as the Warburg effect, is a common aspect 
in various cancer cells that rely on less efficient aerobic 
glycolysis to achieve their energy requirements, due 
to defects in the oxidative phosphorylation metabolic 
pathway [15]. Generation of ATP through glycolysis 
may better meet the energy needs of rapidly proliferating 
cells, enabling them to generate the necessary increasing 
levels of biosynthetic intermediates [16]. In addition, 
the consequent lactic acid production under aerobic 
condition may contribute to the oncogenic process via 
decreased extracellular pH, leading to increased activity 
of proinvasion factors, such as matrix metalloproteases 
[17]. Our proteomic analysis identified enzymes acting 
at the energy-producing metabolic pathway levels that 
lead to an unusually high production of cancer-promoting 
compounds. These metabolic and mitochondrial alterations 
occurring in ACC can offer a window of opportunity for 
efficient and selective anti-cancer therapies [18], which are 
still limited for this tumor. 
For instance, an increased use of the pentose 
phosphate pathway may be triggered by the tumor-
specific pyruvate kinase isoform (PKM2), which 
converts phosphoenolpyruvate to pyruvate and is highly 
expressed in ACC. This enzyme isoform, shifting 
between a less active dimeric and the tetrameric form, 
catalyzes the final limiting step in glycolysis, allowing 
accumulation of phosphometabolites, and so providing 
a high throughput of supply materials from glucose [19]. 
Because catalytic activity of PKM2 is lower, it is thought 
to build up glycolytic intermediates that can be used for 
anabolic pathways. We can assume that activation of 
PKM2 depletes intermediates, thus resulting in a reduced 
proliferation rate of cancer cells. 
Aldo-keto reductase 1 member B1 (AKR1B1) that 
drives glucose flux through the polyol pathway, is also 
highly expressed in ACC and may play a critical role in 
tumor development and progression through carbonyl 
detoxification, retinoic acid homeostatic regulation, and 
lipid metabolic control [20]. This enzyme is involved 
in diabetic complications, and a variety of AKR1B1 
inhibitors have been developed for the treatment of 
diabetic patients [21]. The clinical and preclinical data 
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collected over decades by diabetologists would greatly 
assist the transition of these inhibitors to the clinic of 
ACC.
One of the most interesting proteins highlighted 
by 2D-DIGE analysis is ALDH6A1, a member of 
the aldehyde dehydrogenase family. These enzymes 
show an increased activity in cancer cells, where they 
are focused in protecting against apotosis induced 
by the high levels of reactive oxygen species (ROS) 
generated in the tumor environment. Nevertheless, this 
specific isoform is a mitochondrial methylmalonate 
semialdehyde dehydrogenase that catalyzes valine and 
pyrimidine catabolism to produce acetyl-CoA, the key 
hub of metabolic networks. Its upregulation is inversely 
correlated to progression-free survival in metastatic 
colon cancer [22]. The lack of the enzyme in normal 
adrenal versus its high level of diffuse expression 
in ACC, as further validated by Western blot and 
immunohistochemical analysis, suggests it could be a 
promising specific biomarker for future ACC therapies.
A further correlation between glucose homeostasis, 
lipid metabolism and cell invasiveness in ACC is the 
expression of adenylyl cyclase-associated protein 1 
(CAP-1), involved in the cytoskeletal organization 
and cell adhesion through its role in activating focal 
adhesion kinase (FAK) [23]. This protein has recently 
been demonstrated to be a functional receptor for human 
resistin, coordinating resistin-mediated inflammation 
in obesity [24]. Indeed, the adipose tissue surrounding 
and abundantly infiltrating the adrenocortex might not 
only act as a passive bystander in ACC. A strict crosstalk 
between the tumor microenvironment, including the 
adipocyte components, has recently been claimed to 
sustain cancer progression, mainly by modulating 
metabolic activity and providing fuel to cancer cells [25]. 
A close relationship between obesity and cancer has been 
suggested, and resistin, which is a specific inflammatory 
cytokine produced by the adipose tissue, may contribute 
to supporting the oxidative stress process which regulates 
tumor metabolic homeostasis [26]. Interestingly, in 
ACC, CAP-1 expression is accompanied by a parallel 
upregulation of fascin-1, another actin-bundling protein 
that crosslinks actin filaments into tight, parallel bundles in 
filopodia and invadopodia. In pancreatic cancer, a hypoxic 
tumor microenvironment might promote invasion and 
metastasis by inducing fascin overexpression. Fascin-1 
might be targeted to block cancer progression [27] 
considering that several small-molecule inhibitors have 
recently been designed [28]. 
Contrary to a previous study describing decreased 
levels of enzymes in the respiratory chain in malignant 
adrenal tissue [11], our 2D-DIGE analysis could detect 
only one downregulated protein in tumor condition: 
thiosulfate sulfurtransferase (TST). Reduced activity 
of this sulfide-detoxifying enzyme had previously been 
associated with colon cancer progression [29].
Our study has some limitations, such as the low 
number of the ACC samples, explained by the rarity of 
the tumor. In fact, this limited number does not allow any 
correlation to the patient clinical data. Larger confirmatory 
multicenter studies are necessary to endorse our results. 
Moreover, the small number of samples did not allow 
any specific evaluation of the proteins found as putative 
biomarkers of ACC by the use of a dedicated software 
such as EDA. The 2D-DIGE approach may underestimate 
protein downregulation in ACC compared with normal 
adrenal. Differences in proteins identified as differentially 
expressed in our study compared with previous ones 
[11,12] may be due to the techniques used for protein 
separation, as well as to differences in tumor samples and 
corresponding controls (adenoma or normal adrenals). 
Finally, it was not possible to compare ACC with normal 
adrenal specimens from the same patients, as the tumor 
usually invades all normal adrenal cortex, making it 
difficult to dissect normal tissue. For this reason, we had 
to use normal adrenals from different donors as controls, 
thus introducing a further grade of variability.
In conclusion, through the use of a 2D-DIGE 
approach applied for the first time to the screening 
of proteomic expression in ACC, we identified an 
overexpression protein profile associated with ACC. 
This specific profile suggests metabolic reprogramming 
from aerobic respiration to aerobic glycolysis, known 
as the Warburg effect, which has now been suggested to 
also occur in adrenocortical cancer. The discovery that 
these key enzymes also play a role in the development 
and progression of this tumor opens new avenues for 
their use as potential targets for more efficacious ACC 
therapies [30]. Immunohistochemistry and Western blot 
validation of a restricted panel of 6 proteins designates 
them as potential biomarkers for supporting diagnosis 
and prognosis. Further studies including larger cohorts of 
ACC and benign adrenocortical adenomas are needed to 
validate our encouraging preliminary results and enable 
correlations with clinical data, in an attempt to confer any 
diagnostic and prognostic significance to these biomarkers. 
METHODS
Patients
All patients, or their parents in the case of pediatric 
patients, gave their written informed consent to the study. 
The study includes 10 patients affected by ACC, whose 
clinical characteristics are detailed in Tab.1. All patients 
underwent surgical removal of the tumor at our University 
Hospital. Normal adrenal specimens were obtained at 
radical nephrectomy for renal carcinoma or from organ 
donors (n=8). Tumor (ACC) specimens and normal 
adrenal (NOR) samples were snap frozen and stored at 
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-80°C until protein extraction, or were formalin-fixed/
paraffin-embedded for immunohistochemistry. Double 
sampling was performed in tumor biopsy of patient 2 
resulting in 2 independent samples to be analyzed (ACC2 
and ACC2a).
The study was approved by the Local Ethical 
Committee.
2D-differential-in-gel-electrophoresis (2D-DIGE) 
Tissue samples were homogenized by mechanical 
disruption with Ultraturrax T10 basic IKA (Werke 
Gmbh & Co, Staufen, Germany) in lysis buffer (30 mM 
Tris, pH 8.5, 7 M urea, 2 M thiourea, 4% CHAPS). The 
protein extracts were further treated with the PlusOne 
2-D Clean-Up Kit and quantified with 2-D quant Kit (GE 
Healthcare, Milan, Italy). Fifty µg of each sample were 
minimally labeled with 400 pmol CyDyes DIGE Fluors 
(GE Healthcare): Cy3 and Cy5 for ACC (n=11) and NOR 
(n=8) samples, respectively, and incubated on ice in the 
dark for 30 min. An internal standard was generated by 
combining equal amounts of extracts from all ACC and 
NOR samples and labeled with Cy2. 
A total of 10 2D-gels were run separating 2 
arbitrarily paired samples of ACC and normal adrenal. 
The samples were focused using immobilized pH gradient 
IPG strips (3-10 NL range, 18 cm) onto an IPGphor (GE 
Healthcare) apparatus (67 kVh, 20°C). After focusing, 
each strip was equilibrated twice, and then loaded and 
separated on a 12 % polyacrylamide SDS-PAGE gel using 
a DALT six (GE Healthcare) apparatus. Images were 
acquired with a Typhoon TRIO scanner (GE Healthcare) 
using specific emission filters. Images were analyzed using 
DeCyder Differential Analysis Software v7.2. Intragel 
spot detection and quantification were performed by 
Differential In-gel Analysis (DIA) DeCyder module, while 
Biological Variation Analysis (BVA) module, which takes 
into account intergel variability, was used for matching 
and quantifying the total set of protein spots from all 
gels simultaneously analyzed. DIA component draws 
boundaries around spots in a composite gel image obtained 
from the intragel overlap of the Cy2-, Cy3-, and Cy5-
scanned images and normalizes the data from each CyDye 
to account for differences in dye fluorescence intensity 
and scanner sensitivity. For all sets of experiments (10 
images), the difference in abundance between samples 
(ACC and NOR) run on the same gel was analyzed. BVA 
component was then used to match all image comparisons 
from individual Cy3/Cy5 gel sets for cross-gel statistical 
analysis. BVA calculates normalized intensities (standard 
abundance) for all spots by comparison with the internal 
standard, and then, an average volume ratio and relative 
p-value by Student’s paired t-test . Only spots with 2-fold 
changes in volume after normalization in at least three 
separate experiments (p<0.05) were considered altered and 
selected for further characterization. 
Extended Data Analysis (EDA) component of 
DeCyder software was used to construct the heat-map of 
differential protein expression between tumor and normal 
adrenal samples.
Protein identification by NanoLC-nanoESI-MS/
MS
Preparative 2D-sodium-dodecyl-sulphate-gel-
electrophoresis was run and stained with SYPRO Ruby 
((BIO-RAD Labs, Segrate, Milan, Italy) for protein 
visualization. The spots of interest were automatically 
detected and excised using an Ettan-Picker robot (GE 
Healthcare) and subjected to tryptic digestion. 
Each peptide mixture was submitted to NanoLC-
nanoESI-MS/MS analysis on an Ultimate 3000 HPLC 
(Dionex, San Donato Milanese, Italy) coupled to a LTQ 
Orbitrap mass spectrometer (Thermo Fisher, Bremen, 
Germany). Peptides were concentrated on a precolumn 
cartridge PepMap100 C18 (300μm i.d.×5mm, 5μm, 100Å, 
LC Packings Dionex) and then eluted on an Acclaim 
PepMap100 nano-column (75μm i.d.×15cm, C18, 3μm, 
100Å, LC Packings Dionex) at 300 nl/min. The loading 
mobile phases were: 0.1% TFA in H2O (phase A) and 
0.1% TFA in CH3CN (phase B). The elution mobile phases 
composition was: H2O 0.1% formic acid/CH3CN 97/3 
(phase A) and CH3CN 0.1% formic acid/ H2O 97/3 (phase 
B). The elution program lasted: 0 min, 4% B; 10 min, 40% 
B; 30 min, 65% B; 35 min, 65% B; 36 min, 90% B; 40 
min, 90% B; 41 min, 4%B; 60 min, 4% B. Mass spectra 
were acquired in positive ion mode, setting the spray 
voltage at 2 kV, the capillary voltage and temperature 
respectively at 45 V and 200 °C, and the tube lens at 130 V. 
Data were acquired in data-dependent mode with dynamic 
exclusion enabled (repeat count 2, repeat duration 15 s, 
exclusion duration 30 s); survey MS scans were recorded 
in the Orbitrap analyzer in the mass range 300-2000 
m/z at a 15,000 nominal resolution at m/z = 400; then 
up to three most intense ions in each full MS scan were 
fragmented (isolation width 3 m/z, normalized collision 
energy 30) and analyzed in the IT analyzer. Monocharged 
ions did not trigger MS/MS experiments. The acquired 
data sought with Proteome Discoverer 1.2 (Thermo 
Scientific, Waltham, MA, US) using Sequest as search 
algorithm against Human Protein database. Searches were 
performed allowing: (i) up to two missed cleavage sites, 
(ii) 10 ppm of tolerance for the monoisotopic precursor 
ion and 0.8 mass unit for monoisotopic fragment ions, 
(iii) carbamidomethylation of cysteine and oxidation of 
methionine as variable modifications. We only accepted 
peptides displaying high confidence and proteins with: 
(i) at least two spectra representing two distinct peptides 
and (ii) protein score higher than 30. The obtained peptide 
masses were matched with the theoretical peptide masses 
of all proteins from the human database of the NCBInr 
Oncotarget5704www.impactjournals.com/oncotarget
using MASCOT with the automated MASCOT Daemon 
(Matrix Sciences v2.1, UK). 
Monodimensional sodium-dodecyl-sulphate-gel-
electrophoresis (SDS-PAGE) and Western blot 
analysis
Fifty µg of samples containing equal amounts 
of all ACC or NOR samples, used for 2D-DIGE, 
were separated by reducing monodimensional SDS-
PAGE (10% polyacrylamide) and transferred to PVDF 
membranes (Merck-Millipore, Milan, Italy). Protein 
bands were revealed by primary antibodies (sc-271582 
anti-ALDH6A1, sc-52256 anti-Transferrin, sc-46675 anti-
Fascin-1, sc-6215 anti-Lamin A/C, sc-376512 anti-CAP-1, 
sc-374436 anti-Ferredoxin-reductase, sc-1615 anti-Actin, 
Santa Cruz Biotechnology) followed by peroxidase-
secondary IgG and ECL detection kit (Immobilon, Merck-
Millipore, Milan, Italy). Image acquisition and relative 
quantification of band intensity on actin was performed on 
ChemiDoc XRS instrument with Quantity One software 
(BIO-RAD Labs, Milan, Italy). 
Functional classification of proteins and pathway 
analysis 
A functional study with Gene Ontology (GO) [31] 
over-representation analysis was performed with the 
Biological Network Gene Ontology (BINGO) plug-in 
for the Cytoscape visualization software [32] correcting 
p-values for multiple testing and using a Benjamini 
and Hochberg False Discovery Rate corrected p-value 
threshold of 0.01 [33]. 
Histologic diagnosis and immunohistochemistry
Histologic diagnosis of ACC was performed by 
reference pathologist on tumor tissue removed at surgery. 
Tumor specimens were evaluated according to the Weiss 
System where the presence of three or more criteria highly 
correlates with malignant behavior [34].
Ki67 index was evaluated as proliferation marker to 
assess ACC prognosis using anti-human Ki67 monoclonal 
MIB1 antibody (Dako, Carpenteria, CA, US). Ki67 
positive nuclei were counted on 1.000 tumor cells and 
Ki67 was expressed as the percentage of proliferating 
cells.
Tumor stage was evaluated according to the revised 
TNM classification of ACC proposed by the European 
Network for the Study of Adrenal Tumors [13].
For immunohistochemical analysis, section of 
3μm were deparaffinized, hydrated with grade ethanol 
concentrations until distilled water. Serial sections of 
the same specimen were immunostained with mouse 
monoclonal anti-ALDH6A1, anti-Fascin-1, anti-CAP-1, 
anti-Lamin A/C, anti-Ferredoxin-reductase, anti-
Transferrin (dilution 1:50) antibodies after treatement 
with 3.0% hydrogen peroxidase in PBS (Dako Wash 
Buffer 10x). Immunohistochemical analysis was carried 
out using DAKO EnVision™ FLEX (Dako, Carpenteria, 
CA, US).. Negative control was performed with a non-
immune serum.
Statistical analysis
The relative levels of stained protein spots compared 
with the internal standard spots were analyzed by DeCyder 
Difference In-gel Analysis (DIA) and DeCyder Biological 
Variation Analysis (BVA) software modules (GE 
Healthcare).
Student’s t-test was used to calculate statistically 
significant differences between 2 groups in relative 
abundance of individual protein spots among the groups 
in 2D-DIGE and in protein band intensity in Western blot 
analysis. P<0.05 was considered statistically significant. 
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